{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T03:26:22Z","timestamp":1776309982246,"version":"3.50.1"},"reference-count":70,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anti-infective Therapy"],"published-print":{"date-parts":[[2014,7,1]]},"DOI":"10.1586\/14787210.2014.915738","type":"journal-article","created":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T11:30:49Z","timestamp":1401881449000},"page":"735-742","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":30,"title":["Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults"],"prefix":"10.1586","volume":"12","author":[{"given":"Aditya K","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Mediprobe Research Inc., London, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanne","family":"Daigle","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc., London, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,6,4]]},"reference":[{"key":"CIT0001","author":"Gupta AK","year":"2013","journal-title":"J Am Podiatr Med Assoc"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2008.01606.x"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0804878"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2012.01551.x"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.730"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200001010-00002"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.3.353"},{"issue":"1","key":"CIT0008","first-page":"154","volume":"81","author":"Shuster S","year":"2001","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"CIT0009","first-page":"41","volume":"10","author":"Haneke E","year":"1991","journal-title":"Sem Dermatol"},{"key":"CIT0010","author":"Sigurgeirsson B","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)02117-0"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.107754"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.0014"},{"issue":"1","key":"CIT0014","first-page":"37","volume":"8","author":"Sehgal VN","year":"2010","journal-title":"Skinmed"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.3314\/jjmm.46.77"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.104794"},{"issue":"7","key":"CIT0017","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/j.1468-3083.2006.01631.x","volume":"20","author":"Sigurgeirsson B","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2007.00109.x"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.7547\/87507315-91-9-456"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01281.x"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0507.2003.00855.x"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2006.01230.x"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01107.x"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01282.x"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1997.00163.x"},{"issue":"12","key":"CIT0026","first-page":"1275","volume":"130","author":"Fouilloux B","year":"2003","journal-title":"Ann Dermatol Venereol"},{"issue":"11","key":"CIT0027","first-page":"1263","volume":"12","author":"Daniel RC","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05242.x"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.06.011"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2005.01284.x"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2009.01107.x"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2006.01351.x"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.03.021"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0152-x"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(01)00989-9"},{"key":"CIT0036","unstructured":"Galderma Ltd Product monograph Curanail (5% amorolfine hydrochloride) nail lacquer. Available from: www.mhra.gov.uk\/home\/groups\/l-unit1\/documents\/websiteresources\/con2023787.pdf [Last accessed 3 January 2014]"},{"key":"CIT0037","unstructured":"Dermik Laboratories Product monograph Penlac (ciclopirox topical solution, 8% w\/w) nail lacquer. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/21022s004lbl.pdf [Last accessed 3 January 2014]"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1159\/000247612"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.109071"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.013"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1985.tb00537.x"},{"key":"CIT0042","unstructured":"Novartis Pharmaceuticals. A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or 48 weeks of treatment in patients with mild to moderate toenail onychomycosis. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00443820?term=terbinafine+nail+solution&rank=1 [Last accessed 3 January 2014]"},{"key":"CIT0043","unstructured":"Novartis Pharmaceuticals. A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or 48 weeks of treatment in patients with mild to moderate toenail onychomycosis (NCT00443898). Clinicaltrials.gov, (2007). Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00443898?term=terbinafine+nail+solution&rank=2 [Last accessed 3 January 2014]"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00083-11"},{"key":"CIT0045","unstructured":"Celtic Pharma Development Services. TDT 067 onychomycosis study. clinicaltrials.gov, (2012). Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01145807 [Last Accessed 3 January 2014]"},{"key":"CIT0046","unstructured":"Topica Pharmaceuticals. Safety and efficacy of luliconazole solution, 10% in subjects with mild to moderate onychomycosis. clinicaltrials.gov, (2013). Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01431820 [Last accessed 3 January 2014]"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.2.157"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1021\/jm0603724"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(09)80305-8"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(03)00025-1"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02063-12"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1126\/science.1142189"},{"key":"CIT0053","unstructured":"Beutner KR, Sanders V, Hold K, et al. An open-label, multi-dose study of the absorption and systemic pharmacokinetics of AN2690 applied as a 7.5% solution to all toenails of adult patients with moderate to severe onychomycosis. Anacor.com, (2007) Available from: http:\/\/anacor.com\/pdf\/poster_1823.pdf [Last accessed 14 January 2014]"},{"key":"CIT0054","unstructured":"Mao W, Rock F, Alley MRK. AN2690, a topical antifungal agent in development for the treatment of onychomycosis represents a new class and has a novel mechanism of action. Anacor.com, (2006) Available from: www.anacor.com\/pdf\/SID_P769.pdf [Last accessed 14 January 2014]"},{"key":"CIT0055","unstructured":"Hold KM, Bu W, Sanders V, et al. In vivo nail residence time of AN2690, a novel broad-spectrum antifungal agent in development for the topical treatment of onychomycosis. Anacor.com, (2007) Available from: http:\/\/anacor.com\/pdf\/poster_1816.pdf [Last accessed 14 January 2014]"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20901"},{"key":"CIT0057","unstructured":"Sanders V, Baker SJ, Alley MRK, et al. Microbiological activity of AN2690, a new antifungal agent in development for the topical treatment of onychomycosis. Anacor.com, (2006) Available from: http:\/\/anacor.com\/pdf\/AAD_P1608.pdf [Last accessed 14 January 2014]"},{"key":"CIT0058","first-page":"662","volume":"8","author":"Barak O","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"CIT0059","unstructured":"Beutner KR, Sanders V, Hold K, et al. An open-label, multi-dose study of the absorption and systemic pharmacokinetics of AN2690 applied as a 7.5% solution to all toenails of adult patients with moderate to severe onychomycosis. Anacor.com, (2007) Available from: http:\/\/anacor.com\/pdf\/poster_1823.pdf [Last accessed 17 January 2014]"},{"key":"CIT0060","unstructured":"Beutner K, Toledo-Bahena M, Barbosa-Alanis H, et al. Interim results of a multi-center study to evaluate the safety and efficacy of topically applied AN2690 5.0% and 7.5% solutions for the treatment of onychomycosis of the great toenail. Anacor.com, (2006) Available from: www.anacor.com\/pdf\/ESDR_P565.pdf [Last accessed 17 January 2014]"},{"key":"CIT0061","unstructured":"Zane L, Pollak R. Safety and efficacy of tavaborole (formerly AN2690), a novel boron-based molecule, in phase 2 trials for the topical treatment of toenail onychomycosis. Anacor.com, (2012) Available from: www.anacor.com\/pdf\/APMA%20Tavaborole%20Phase%202%20Poster.pdf [Last accessed 17 January 2014]"},{"key":"CIT0062","unstructured":"Elewski BE, Rich P, Wiltz H, et al. Effectiveness and safety of tavaborole, a novel boron-based molecule for the treatment of onychomycosis: results from two phase 3 studies. Anacor.com, (2013) Available from: http:\/\/anacor.com\/pdf\/Tavaborole_Phase%203%20Poster_Final%20Copy_093013.pdf [Last accessed 17 January 2014]"},{"issue":"4","key":"CIT0063","first-page":"663","volume":"63","author":"Rodgers P","year":"2001","journal-title":"Am Fam Physician"},{"key":"CIT0064","unstructured":"Chanda S, Liu L, Heyman I. Preclinical safety studies with AN2690, a novel boron-containing small molecule for topical treatment of onychomycosis, demonstrate promising safety profile. Anacor.com, (2011) Available from: http:\/\/anacor.com\/pdf\/ESDR_AN2690_223.pdf [Last accessed 3 January 2014]"},{"key":"CIT0065","unstructured":"Anacor Pharmaceuticals Inc. Anacor Pharmaceuticals announces FDA acceptance of tavaborole NDA for filling. Anacor.com, (2013). Available from: http:\/\/investor.anacor.com\/releasedetail.cfm?ReleaseID=794323 [Last accessed 17 January 2014]"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03164.x"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2013.06.010"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.149.s65.5.x"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(02)80040-6"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1080\/09546630050517207"}],"container-title":["Expert Review of Anti-infective Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/14787210.2014.915738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T09:03:55Z","timestamp":1716800635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/14787210.2014.915738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,4]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7,1]]}},"alternative-id":["10.1586\/14787210.2014.915738"],"URL":"https:\/\/doi.org\/10.1586\/14787210.2014.915738","relation":{},"ISSN":["1478-7210","1744-8336"],"issn-type":[{"value":"1478-7210","type":"print"},{"value":"1744-8336","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-06-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}